Michelle W Sahli1, Julie A Mares2, Kristin J Meyers2, Ronald Klein2, William E Brady3, Barbara E K Klein2, Heather M Ochs-Balcom4, Richard P Donahue4, Amy E Millen4. 1. a Department of Public Health and Health Sciences, School of Health Professions and Studies , University of Michigan-Flint , Flint , MI , USA. 2. b Department of Ophthalmology and Visual Sciences , University of Wisconsin-Madison , Madison , WI , USA. 3. c Department of Biostatistics and Bioinformatics , Roswell Park Cancer Institute , Buffalo , NY , USA. 4. d Department of Epidemiology and Environmental Health, School of Public Health and Health Professions , University at Buffalo, The State University of New York , Buffalo , NY , USA.
Abstract
PURPOSE: We tested the hypothesis that dietary intake of lutein is inversely associated with prevalence of diabetic retinopathy (DR) due to its antioxidant and anti-inflammatory properties and location within the retina. METHODS: We used logistic regression to examine the association between prevalent DR and energy-adjusted lutein intake by quartile (Q) using data collected from 1430 Atherosclerosis Risk in Communities Study (ARIC) participants with diabetes (n = 994 white, n = 508 black). DR was assessed from 45° non-mydriatic retinal photographs of one randomly chosen eye taken at visit 3 (1993-1995). Dietary lutein intake was estimated using a 66-item food frequency questionnaire at visit 1 (1987-1989). RESULTS: Median estimated daily lutein intake was 1370 µg/1000 kcals and prevalence of DR was ~21%. We found a crude association between lutein and DR (odds ratio, OR, 2.11, 95% confidence interval, CI, 1.45-3.09 for Q4, high intake, vs. Q1, low intake; p for trend <0.0001), which was attenuated after adjustment for ethnicity, duration of diabetes, glycosylated hemoglobin levels, field center and energy intake (OR 1.41, 95% CI 0.87-2.28; p for trend = 0.01). In analyses limited to persons with short diabetes duration (<6 years), the association no longer persisted (OR 0.94, 95% CI 0.31-2.16; p for trend =0.72) compared to the association in those with longer diabetes duration (≥6 years; OR 1.58, 95% CI 0.91-2.75; p for trend = 0.01). CONCLUSION: Contrary to our hypothesis, we found that the odds of higher lutein intake were greater among those with DR than those without DR. However, after adjusting for confounders, intake of lutein was not associated with DR.
PURPOSE: We tested the hypothesis that dietary intake of lutein is inversely associated with prevalence of diabetic retinopathy (DR) due to its antioxidant and anti-inflammatory properties and location within the retina. METHODS: We used logistic regression to examine the association between prevalent DR and energy-adjusted lutein intake by quartile (Q) using data collected from 1430 Atherosclerosis Risk in Communities Study (ARIC) participants with diabetes (n = 994 white, n = 508 black). DR was assessed from 45° non-mydriatic retinal photographs of one randomly chosen eye taken at visit 3 (1993-1995). Dietary lutein intake was estimated using a 66-item food frequency questionnaire at visit 1 (1987-1989). RESULTS: Median estimated daily lutein intake was 1370 µg/1000 kcals and prevalence of DR was ~21%. We found a crude association between lutein and DR (odds ratio, OR, 2.11, 95% confidence interval, CI, 1.45-3.09 for Q4, high intake, vs. Q1, low intake; p for trend <0.0001), which was attenuated after adjustment for ethnicity, duration of diabetes, glycosylated hemoglobin levels, field center and energy intake (OR 1.41, 95% CI 0.87-2.28; p for trend = 0.01). In analyses limited to persons with short diabetes duration (<6 years), the association no longer persisted (OR 0.94, 95% CI 0.31-2.16; p for trend =0.72) compared to the association in those with longer diabetes duration (≥6 years; OR 1.58, 95% CI 0.91-2.75; p for trend = 0.01). CONCLUSION: Contrary to our hypothesis, we found that the odds of higher lutein intake were greater among those with DR than those without DR. However, after adjusting for confounders, intake of lutein was not associated with DR.
Authors: Eva Lonn; Salim Yusuf; Byrcon Hoogwerf; Janice Pogue; Qilong Yi; Bernard Zinman; Jackie Bosch; Gilles Dagenais; Johannes F E Mann; Hertzel C Gerstein Journal: Diabetes Care Date: 2002-11 Impact factor: 19.112
Authors: Mohammad Shamsul Ola; Mohd Imtiaz Nawaz; M Mairaj Siddiquei; Saleh Al-Amro; Ahmed M Abu El-Asrar Journal: J Diabetes Complications Date: 2012-01-05 Impact factor: 2.852
Authors: W C Willett; L Sampson; M J Stampfer; B Rosner; C Bain; J Witschi; C H Hennekens; F E Speizer Journal: Am J Epidemiol Date: 1985-07 Impact factor: 4.897
Authors: Amy E Millen; Ronald Klein; Aaron R Folsom; June Stevens; Mari Palta; Julie A Mares Journal: Am J Clin Nutr Date: 2004-05 Impact factor: 7.045
Authors: Amy E Millen; Michael Gruber; Ron Klein; Barbara E K Klein; Mari Palta; Julie A Mares Journal: Am J Epidemiol Date: 2003-08-01 Impact factor: 4.897
Authors: Chao Yang; Lucia Kwak; Shoshana H Ballew; Bernard G Jaar; Jennifer A Deal; Aaron R Folsom; Gerardo Heiss; A Richey Sharrett; Elizabeth Selvin; Charumathi Sabanayagam; Josef Coresh; Kunihiro Matsushita Journal: Atherosclerosis Date: 2019-10-11 Impact factor: 5.162
Authors: Mark Y Z Wong; Ryan E K Man; Eva K Fenwick; Preeti Gupta; Ling-Jun Li; Rob M van Dam; Mary F Chong; Ecosse L Lamoureux Journal: PLoS One Date: 2018-01-11 Impact factor: 3.240
Authors: Jingyao Hong; Aditya Surapaneni; Natalie Daya; Elizabeth Selvin; Josef Coresh; Morgan E Grams; Shoshana H Ballew Journal: Kidney Med Date: 2021-07-07